A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: What is new?

Shankar Vallabhajosula, Lilja Solnes, Brigitte Vallabhajosula

Research output: Contribution to journalArticle

Abstract

Positron emission tomography (PET)/computed tomography (CT) is a rapidly expanding imaging modality, thanks to the availability of compact medical cyclotrons and automated chemistry synthesis modules for the production of PET radiopharmaceuticals. Despite the availability of many radiotracers, [ 18F]fluorodeoxyglucose (FDG) is currently the most widely used radiopharmaceutical in PET, and the field of molecular imaging is anxiously awaiting the introduction of new PET radiopharmaceuticals for routine clinical use. During the last five years, several proprietary PET radiopharmaceuticals have been developed by major companies, and these new agents are in different stages of clinical evaluation. These new PET drugs are designed for imaging brain beta amyloid, myocardial perfusion, amino acid transport, angiogenesis, and tumor antigen expression. In addition, the National Cancer Institute, Society of Nuclear Medicine Clinical Trials Network, and the American College of Radiology Imaging Network have been conducting multicenter clinical trials with several nonproprietary PET drugs such as sodium [18F]fluoride, [18F]fluorothymidine, [18F]fluoromisonidazole, and 64Cu-labeled diacetyl-bis (N4-methylthiosemicarbazone. All new PET radiopharmaceuticals, like any other drugs, must be manufactured under current good manufacturing practices as required by the Food and Drug Administration before clinical evaluation (phases I, II, and III) and submission of new drug application. This review briefly describes the chemistry, mechanisms(s) of localization, and clinical application of both proprietary and nonproprietary new PET drugs under multicenter clinical evaluation.

Original languageEnglish (US)
Pages (from-to)246-264
Number of pages19
JournalSeminars in Nuclear Medicine
Volume41
Issue number4
DOIs
StatePublished - Jul 2011
Externally publishedYes

Fingerprint

Radiopharmaceuticals
Positron-Emission Tomography
Pharmaceutical Preparations
Clinical Trials
Cyclotrons
Diacetyl
Sodium Fluoride
Molecular Imaging
National Cancer Institute (U.S.)
Fluorodeoxyglucose F18
Neoplasm Antigens
United States Food and Drug Administration
Amyloid
Radiology
Neuroimaging
Multicenter Studies
Perfusion
Amino Acids

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

A broad overview of positron emission tomography radiopharmaceuticals and clinical applications : What is new? / Vallabhajosula, Shankar; Solnes, Lilja; Vallabhajosula, Brigitte.

In: Seminars in Nuclear Medicine, Vol. 41, No. 4, 07.2011, p. 246-264.

Research output: Contribution to journalArticle

@article{069298b367664addb544b1294e091ad8,
title = "A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: What is new?",
abstract = "Positron emission tomography (PET)/computed tomography (CT) is a rapidly expanding imaging modality, thanks to the availability of compact medical cyclotrons and automated chemistry synthesis modules for the production of PET radiopharmaceuticals. Despite the availability of many radiotracers, [ 18F]fluorodeoxyglucose (FDG) is currently the most widely used radiopharmaceutical in PET, and the field of molecular imaging is anxiously awaiting the introduction of new PET radiopharmaceuticals for routine clinical use. During the last five years, several proprietary PET radiopharmaceuticals have been developed by major companies, and these new agents are in different stages of clinical evaluation. These new PET drugs are designed for imaging brain beta amyloid, myocardial perfusion, amino acid transport, angiogenesis, and tumor antigen expression. In addition, the National Cancer Institute, Society of Nuclear Medicine Clinical Trials Network, and the American College of Radiology Imaging Network have been conducting multicenter clinical trials with several nonproprietary PET drugs such as sodium [18F]fluoride, [18F]fluorothymidine, [18F]fluoromisonidazole, and 64Cu-labeled diacetyl-bis (N4-methylthiosemicarbazone. All new PET radiopharmaceuticals, like any other drugs, must be manufactured under current good manufacturing practices as required by the Food and Drug Administration before clinical evaluation (phases I, II, and III) and submission of new drug application. This review briefly describes the chemistry, mechanisms(s) of localization, and clinical application of both proprietary and nonproprietary new PET drugs under multicenter clinical evaluation.",
author = "Shankar Vallabhajosula and Lilja Solnes and Brigitte Vallabhajosula",
year = "2011",
month = "7",
doi = "10.1053/j.semnuclmed.2011.02.003",
language = "English (US)",
volume = "41",
pages = "246--264",
journal = "Seminars in Nuclear Medicine",
issn = "0001-2998",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - A broad overview of positron emission tomography radiopharmaceuticals and clinical applications

T2 - What is new?

AU - Vallabhajosula, Shankar

AU - Solnes, Lilja

AU - Vallabhajosula, Brigitte

PY - 2011/7

Y1 - 2011/7

N2 - Positron emission tomography (PET)/computed tomography (CT) is a rapidly expanding imaging modality, thanks to the availability of compact medical cyclotrons and automated chemistry synthesis modules for the production of PET radiopharmaceuticals. Despite the availability of many radiotracers, [ 18F]fluorodeoxyglucose (FDG) is currently the most widely used radiopharmaceutical in PET, and the field of molecular imaging is anxiously awaiting the introduction of new PET radiopharmaceuticals for routine clinical use. During the last five years, several proprietary PET radiopharmaceuticals have been developed by major companies, and these new agents are in different stages of clinical evaluation. These new PET drugs are designed for imaging brain beta amyloid, myocardial perfusion, amino acid transport, angiogenesis, and tumor antigen expression. In addition, the National Cancer Institute, Society of Nuclear Medicine Clinical Trials Network, and the American College of Radiology Imaging Network have been conducting multicenter clinical trials with several nonproprietary PET drugs such as sodium [18F]fluoride, [18F]fluorothymidine, [18F]fluoromisonidazole, and 64Cu-labeled diacetyl-bis (N4-methylthiosemicarbazone. All new PET radiopharmaceuticals, like any other drugs, must be manufactured under current good manufacturing practices as required by the Food and Drug Administration before clinical evaluation (phases I, II, and III) and submission of new drug application. This review briefly describes the chemistry, mechanisms(s) of localization, and clinical application of both proprietary and nonproprietary new PET drugs under multicenter clinical evaluation.

AB - Positron emission tomography (PET)/computed tomography (CT) is a rapidly expanding imaging modality, thanks to the availability of compact medical cyclotrons and automated chemistry synthesis modules for the production of PET radiopharmaceuticals. Despite the availability of many radiotracers, [ 18F]fluorodeoxyglucose (FDG) is currently the most widely used radiopharmaceutical in PET, and the field of molecular imaging is anxiously awaiting the introduction of new PET radiopharmaceuticals for routine clinical use. During the last five years, several proprietary PET radiopharmaceuticals have been developed by major companies, and these new agents are in different stages of clinical evaluation. These new PET drugs are designed for imaging brain beta amyloid, myocardial perfusion, amino acid transport, angiogenesis, and tumor antigen expression. In addition, the National Cancer Institute, Society of Nuclear Medicine Clinical Trials Network, and the American College of Radiology Imaging Network have been conducting multicenter clinical trials with several nonproprietary PET drugs such as sodium [18F]fluoride, [18F]fluorothymidine, [18F]fluoromisonidazole, and 64Cu-labeled diacetyl-bis (N4-methylthiosemicarbazone. All new PET radiopharmaceuticals, like any other drugs, must be manufactured under current good manufacturing practices as required by the Food and Drug Administration before clinical evaluation (phases I, II, and III) and submission of new drug application. This review briefly describes the chemistry, mechanisms(s) of localization, and clinical application of both proprietary and nonproprietary new PET drugs under multicenter clinical evaluation.

UR - http://www.scopus.com/inward/record.url?scp=79957739301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957739301&partnerID=8YFLogxK

U2 - 10.1053/j.semnuclmed.2011.02.003

DO - 10.1053/j.semnuclmed.2011.02.003

M3 - Article

C2 - 21624560

AN - SCOPUS:79957739301

VL - 41

SP - 246

EP - 264

JO - Seminars in Nuclear Medicine

JF - Seminars in Nuclear Medicine

SN - 0001-2998

IS - 4

ER -